{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:28:22Z","timestamp":1710512902171},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1038\/sj.bjc.6602842","type":"journal-article","created":{"date-parts":[[2005,11,8]],"date-time":"2005-11-08T18:15:32Z","timestamp":1131473732000},"page":"1112-1116","source":"Crossref","is-referenced-by-count":14,"title":["Phase II study of gemcitabine and cisplatin in locally advanced\/metastatic oesophageal cancer"],"prefix":"10.1038","volume":"93","author":[{"given":"J","family":"Millar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Scullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"McClory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Philips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Eatock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,8]]},"reference":[{"key":"BF6602842_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491\u2013498","journal-title":"J Clin Oncol"},{"key":"BF6602842_CR2","first-page":"447","volume":"21","author":"JA Ajani","year":"1994","unstructured":"Ajani JA (1994) Contributions of chemotherapy in the management of carcinoma of the oesophagus: results and commentary. Semin Oncol 21: 447\u2013482","journal-title":"Semin Oncol"},{"key":"BF6602842_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00000421-199202000-00007","volume":"15","author":"AS Alberts","year":"1992","unstructured":"Alberts AS, Schoeman L, Burger W, Greef F, Falkson G (1992) A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus. Am J Clin Oncol 15: 35\u201336","journal-title":"Am J Clin Oncol"},{"key":"BF6602842_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.1994.12.9.1821","volume":"12","author":"H Anderson","year":"1994","unstructured":"Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821\u20131826","journal-title":"J Clin Oncol"},{"key":"BF6602842_CR5","first-page":"521","volume":"2","author":"AM Bergman","year":"1996","unstructured":"Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521\u2013530","journal-title":"Clin Cancer Res"},{"key":"BF6602842_CR6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","volume":"33","author":"H Bleiberg","year":"1997","unstructured":"Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216\u20131220","journal-title":"Eur J Cancer"},{"key":"BF6602842_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/0959-8049(95)00419-X","volume":"31","author":"BJ Braakhuis","year":"1995","unstructured":"Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31: 2335\u20132340","journal-title":"Eur J Cancer"},{"key":"BF6602842_CR8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. J Clin Oncol 15: 2403\u20132413","journal-title":"J Clin Oncol"},{"key":"BF6602842_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1023\/A:1008276507236","volume":"9","author":"D Castellano","year":"1998","unstructured":"Castellano D, Lianes P, Paz-Ares L, Hidalgo M, Guerra JA, Gomez-Martin C, Gomez H, Calzas J, Cortes-Funes H (1998) A phase II study of a novel gemcitabine plus cisplatin regimen administered every 3 weeks for advanced non small cell lung cancer. Ann Oncol 9: 457\u2013459","journal-title":"Ann Oncol"},{"key":"BF6602842_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a058910","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J (1994) A phase II study of gemcitabine in patients with advanced carcinoma of the head and neck. Ann Oncol 5: 543\u2013547","journal-title":"Ann Oncol"},{"key":"BF6602842_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/oxfordjournals.annonc.a058808","volume":"5","author":"Y Cornier","year":"1994","unstructured":"Cornier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D (1994) Gemcitabine is an active agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5: 283\u2013285","journal-title":"Ann Oncol"},{"key":"BF6602842_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0006-2952(02)01508-3","volume":"65","author":"M Crul","year":"2003","unstructured":"Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, Schellens JH (2003) DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 65: 275\u2013282","journal-title":"Biochem Pharmacol"},{"key":"BF6602842_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/annonc\/mdh109","volume":"15","author":"SM De Lange","year":"2004","unstructured":"De Lange SM, van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF, Peters GJ, Pinedo HM, Giaccone G (2004) Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 15: 484\u2013488","journal-title":"Ann Oncol"},{"key":"BF6602842_CR14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1023\/A:1026595525977","volume":"11","author":"V Heinemann","year":"2000","unstructured":"Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ, Arning M, Schalhorn A, Possinger K, Fink U (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11: 1399\u20131403","journal-title":"Ann Oncol"},{"key":"BF6602842_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0169-5002(01)00187-8","volume":"33","author":"C Huisman","year":"2001","unstructured":"Huisman C, Giaccone G, van Groeningen CJ, Sutedja G, Postmus PE, Smit EF (2001) Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. Lung Cancer 33: 267\u2013275","journal-title":"Lung Cancer"},{"key":"BF6602842_CR16","first-page":"316","volume":"6","author":"DH Ilson","year":"2000","unstructured":"Ilson DH, Forrastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen DP (2000) A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6: 316\u2013323","journal-title":"Cancer J"},{"key":"BF6602842_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/IJGC:32:2-3:115","volume":"32","author":"A Jatoi","year":"2002","unstructured":"Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargent D, Goldberg RM (2002) A phase II trial of docetaxel and CPT11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction or gastric cardia. Int J Gastrointest Cancer 32: 115\u2013123","journal-title":"Int J Gastrointest Cancer"},{"key":"BF6602842_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1023\/A:1008339425708","volume":"10","author":"JR Kroep","year":"1999","unstructured":"Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM, van Groeningen CJ (1999) Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 10: 1503\u20131510","journal-title":"Ann Oncol"},{"key":"BF6602842_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/annonc\/mdh063","volume":"15","author":"JR Kroep","year":"2004","unstructured":"Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ (2004) Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol 15: 230\u2013235","journal-title":"Ann Oncol"},{"key":"BF6602842_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0022-5347(05)67447-2","volume":"164","author":"V Lorusso","year":"2000","unstructured":"Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M (2000) Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164: 53\u201356","journal-title":"J Urol"},{"key":"BF6602842_CR21","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","volume":"86","author":"B Lund","year":"1994","unstructured":"Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine in previously treated ovarian cancer patients. J Natl Canc Inst 86: 1530\u20131533","journal-title":"J Natl Canc Inst"},{"key":"BF6602842_CR22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/000313480306900811","volume":"69","author":"MA Makary","year":"2003","unstructured":"Makary MA, Kiernen PD, Sheridan MJ, Tonnesen G, Hetrick V, Vaughan B, Graling P, Elster E (2003) Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy. Am Surg 69: 693\u2013700","journal-title":"Am Surg"},{"key":"BF6602842_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/00001813-200209000-00009","volume":"13","author":"M Nogue","year":"2002","unstructured":"Nogue M, Cirera L, Arcusa A, Batiste-Alentorn E, Balil A, Font A, Perez-Gracia JL, Carrasco EM, Tusquets I (2002) Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 13: 839\u2013845","journal-title":"Anticancer Drugs"},{"key":"BF6602842_CR24","first-page":"72","volume":"22","author":"GJ Peters","year":"1995","unstructured":"Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22: 72\u201379","journal-title":"Semin Oncol"},{"key":"BF6602842_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00001813-199512006-00009","volume":"6","author":"K Possinger","year":"1995","unstructured":"Possinger K (1995) Gemcitabine in advanced breast cancer. Anti-Cancer Drugs 6: 55\u201359","journal-title":"Anti-Cancer Drugs"},{"key":"BF6602842_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1023\/A:1008334610955","volume":"11","author":"M Rinaldi","year":"2000","unstructured":"Rinaldi M, Crino L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, Selvaggi G, Della Giulia M, Darwish S, Porrozzi S, Novello S, Cipri A, Bartolucci R, Calandri C, Tonato M (2000) A three-week schedule of gemcitabine\u2013cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomised trial. Ann Oncol 11: 1295\u20131300","journal-title":"Ann Oncol"},{"key":"BF6602842_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/gyno.2002.6850","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M (2003) Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88: 17\u201321","journal-title":"Gynecol Oncol"},{"key":"BF6602842_CR28","first-page":"3087","volume":"22","author":"D Rossi","year":"2002","unstructured":"Rossi D, Graziano F, Catalano V, Giordani P, Fedeli SL, Alessandroni P, Fedeli A, Dennetta D, Ugolini M, Catalano G (2002) A new cisplatin\/gemcitabine schedule in locally advanced (III) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study. Anticancer Res 22: 3087\u20133092","journal-title":"Anticancer Res"},{"key":"BF6602842_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1023\/A:1008369718242","volume":"11","author":"AB Sandler","year":"2000","unstructured":"Sandler AB, Kindler HL, Einhorn LH, Mitchell E, Masters G, Kraut M, Nicol S, Raghavan D (2000) Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 11: 1161\u20131164","journal-title":"Ann Oncol"},{"key":"BF6602842_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdf186","volume":"13","author":"H Soto Parra","year":"2002","unstructured":"Soto Parra H, Cavina R, Latteri F, Sala A, Dambrosio M, Antonelli G, Morenghi E, Alloisio M, Ravasi G, Santoro A (2002) Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomised phase II study. Ann Oncol 13: 1080\u20131086","journal-title":"Ann Oncol"},{"key":"BF6602842_CR31","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","volume":"15","author":"WM Stadler","year":"1997","unstructured":"Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatis urothelial cancer. J Clin Oncol 15: 3394\u20133398","journal-title":"J Clin Oncol"},{"key":"BF6602842_CR32","first-page":"43","volume":"23","author":"WP Steward","year":"1996","unstructured":"Steward WP, Dunlop DJ, Dabouis G, Lacroix H, Talbot D (1996) Phase I\/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin Oncol 23: 43\u201347","journal-title":"Semin Oncol"},{"key":"BF6602842_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/B:DRUG.0000006179.20974.af","volume":"22","author":"SG Urba","year":"2004","unstructured":"Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL (2004) Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 22: 91\u201397","journal-title":"Invest New Drugs"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602842.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602842","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602842.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T14:17:07Z","timestamp":1706710627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["BF6602842"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602842","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}